Dianthus Therapeutics Inc. (DNTH NASDAQ) stock market data APIs
$83.1708
-0.17(-0.2%)
as of October 9, 2026
Try our APIs with
free plan!
Dianthus Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Prev. Close
83.1708
Open
82.9985
High
85.7147
Low
82.7468
52 wk Range
32.22-117.88
Market Cap
4 607 M
Shares Outstanding
55 934 K
Revenue
1 904 K
EPS
-0.9
Beta
0.181
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Dianthus Therapeutics Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Dianthus Therapeutics Inc. data using free add-ons & libraries
Get Dianthus Therapeutics Inc. Fundamental Data
Dianthus Therapeutics Inc. Fundamental data includes:
- Net Revenue: 1 904 K
- EBITDA: -217 720 992
- Earnings Per Share: -4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Dianthus Therapeutics Inc. Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-04
- EPS/Forecast: -0.93
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dianthus Therapeutics Inc. News
New
Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?
Dianthus Therapeutics (DNTH) has moved into the capital markets spotlight after filing a US$500 million follow on equity offering of common stock alongside a broad universal shelf registration. The c...
Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen
On August 4, Dianthus Therapeutics (NASDAQ:DNTH) reported second-quarter 2026 results alongside a stack of pipeline updates that touched nearly every program the company runs. For a clinical-stage bio...
Dianthus gains new Buy from Citi on multi-blockbuster potential for lead drug
[Wall Street NY] Nikada/E+ via Getty Images Citi on Friday issued a new Buy rating on Dianthus Therapeutics (DNTH [https://seekingalpha.com/symbol/DNTH]), a biotech developing drugs for autoimmune co...
UiPath downgraded, Shell upgraded: Wall Street's top analyst calls
UiPath downgraded, Shell upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that...
Get Dianthus Therapeutics Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.